Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bcr/Abl fusion protein

3

Platelet-derived growth factor receptor alpha

3

Platelet-derived growth factor receptor beta

3

Stem cell growth factor receptor

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2001

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown)

3

Hypereosinophilic syndrome

3

Myelodysplastic/myeloproliferative diseases associated with PDGFR

3

Philadelphia chromosome positive acute lymphoblastic leukemia

3

Philadelphia chromosome positive chronic myeloid leukemia

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Novartis

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA ORPHAN DRUG

3

FDA UNII

3

PUBCHEM

3

CAS

2

CHEBI

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Protein kinase inhibitors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

IMATINIB

BKJ8M8G5HI

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2001

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Bcr/Abl fusion protein

Conditions:

Myelodysplastic/myeloproliferative diseases associated with PDGFR

Hypereosinophilic syndrome

Philadelphia chromosome positive chronic myeloid leukemia

Philadelphia chromosome positive acute lymphoblastic leukemia

Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown)

Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...

inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

IKT-001PRO

WQJ8L8YJ7U

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2001

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Bcr/Abl fusion protein

Conditions:

Myelodysplastic/myeloproliferative diseases associated with PDGFR

Hypereosinophilic syndrome

Philadelphia chromosome positive chronic myeloid leukemia

Philadelphia chromosome positive acute lymphoblastic leukemia

Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown)

Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...

inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

Imatinib Mesylate

8A1O1M485B

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2001

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Bcr/Abl fusion protein

Conditions:

Myelodysplastic/myeloproliferative diseases associated with PDGFR

Hypereosinophilic syndrome

Philadelphia chromosome positive chronic myeloid leukemia

Philadelphia chromosome positive acute lymphoblastic leukemia

Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown)

Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...

inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1